Risk-reducing ovarian cancer surgery and quality of life
https://www.facingourrisk.org/XRAY/risk-reducing-ovarian-cancer-surgery-and-QOL
Full article: https://jamanetwork.com/journals/jamaoncology/fullarticle/2780476
People with an inherited BRCA gene mutation are recommended to have surgery to remove their ovaries before the age of natural menopause to reduce their risk of ovarian cancer. This surgery can cause short-term and long-term effects. This study assesses the quality of life among people who have their fallopian tubes surgically removed and later have their ovaries removed compared to people who have their ovaries and fallopian tubes removed at the same time. (Posted 7/26/22). Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Am I a candidate for RRS followed by delayed RRO to reduce my ovarian cancer risk?
- Do you recommend hormone replacement therapy after RRSO?
- Are there other ways to reduce my menopausal symptoms after RRSO instead of or in addition to hormone replacement therapy?
- Are there other ways to lower my risk for ovarian cancer?
Open Clinical Trials
The following are studies looking at ovarian cancer screening or prevention.
- NCT04251052: A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk). This study is looking at whether women with BRCA1 mutations who remove just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as women who remove their ovaries and fallopian tubes.
- NCT05287451: Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention. This study will look at outcomes in women with BRCA1, BRCA2, BRIP1, RAD51C and RAD51D who remove their fallopian tubes, followed by removal of their ovaries compared to women who undergo standard-of-care removal of their ovaries and fallopian tubes at the same time.
- Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE). The goal of MiDe is to develop a test to detect early-onset ovarian cancer. Currently, no reliable screening or early detection tests are available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. These samples can be collected by mobile phlebotomy all around the US.
- NCT04794322: Developing a Test for the Detection of Ovarian Cancer. This study aims to develop an ovarian cancer early detection test that looks at DNA found in a uterine (womb) washing and proteins found in the blood. Participants will not receive the results of their tests.
Additional clinical trials for ovarian cancer screening and prevention may be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.